UC Davis Comprehensive Cancer Center is the only National Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people. Its specialists provide compassionate, comprehensive care for more than 100,000 adults and children every year and access to more than 200 active clinical trials at any given time. Its innovative research program engages more than 240 scientists at UC Davis who work collaboratively to advance discovery of new tools to diagnose and treat cancer. Patients have access to leading-edge care, including immunotherapy and other targeted treatments. Its Office of Community Outreach and Engagement addresses disparities in cancer outcomes across diverse populations, and the cancer center provides comprehensive education and workforce development programs for the next generation of clinicians and scientists. For more information, visit cancer.ucdavis.edu.
Dinutuximab Plus GM-CSF Does Not Improve DCR in Recurrent Osteosarcoma
R. Lor Randall, MD, FACS, discusses the poor prognosis associated with recurrent pulmonary osteosarcoma, the data from the AOST1421 trial of dinutuxumab plus granulocyte-macrophage colony-stimulating factor, and the need for expanded treatment options in osteosarcoma.
Surgical Complications Unrelated to Timing of Neoadjuvant Chemotherapy in Lower-Extremity Sarcomas
R. Lor Randall, MD, FACS, discusses the findings from a subset analysis of the PARITY trial on the timing of neoadjuvant chemotherapy in patients with lower-extremity sarcomas.
Machine Learning Increases Diagnostic Accessibility, Saves Time in Histopathology
July 13th 2022R. Lor Randall, MD, FACS, shares the successes achieved so far with machine learning in histopathology, explained the positive effect this technology can have on institutions, and advocated for further use of technology to aid treatment advances.
R. Lor Randall, MD, speaks to the findings from a report that said multiple sex-related, racial/ethnic, and socioeconomic status disparities are associated with an increased incidence of metastatic bone disease originating from cancers in the prostate, renal, colon, lung, and breast.
Compressive Osseointegrated Endoprostheses Provide Long-Term Benefit in Bone Sarcoma
November 18th 2021R. Lor Randall, MD, FACS, the 10-year results of a retrospective analysis, potential strategies to mitigate early failures in recipients of compressive osseointegrative endoprosthetic devices, and the need for communication between medical oncologists and orthopedic surgeons to ensure patients on chemotherapy receive optimal care.
Molecular Testing Is Critical With New Targets, Novel Therapies, and Earlier Intervention in NSCLC
October 7th 2021David R. Gandara, highlights key data regarding the earlier integration of targeted therapy in NSCLC, the growing role of molecular testing with tissue and liquid biopsy, and the importance of incorporating a multidisciplinary approach to patient care in the paradigm.
Gandara Named Chief Medical Officer of International Society for Liquid Biopsy
August 4th 2021David R. Gandara, MD has been appointed chief medical officer of the International Society for liquid biopsy, an international non-profit organization dedicated to advancing the field of liquid biopsy in cancer diagnosis and management.
MRD Offers a Potential Predictive Strategy to Further Personalize Treatment in NSCLC
July 29th 2021Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.
Risk-Based Triaged Mammograms Demonstrate Success During Periods of Reduced Capacity
April 28th 2021Triaging individuals with the highest likelihood of cancer detection with their clinical indication and individual risk factors during periods of reduced capacity could be an efficient way of identifying the most cancers with the least examinations compared with a non–risk-based approach.
NCCN Announces UC Davis Comprehensive Cancer Center as 31st Member Institution
April 16th 2021Experts from Northern California-based cancer center to join panels responsible for evidence- based recommendations in NCCN Clinical Practice Guidelines and NCCN Guidelines for Patients, among other resources to improve outcomes for people with cancer.